Explore the revolutionary developments in Synthetic Biology for enhancing the safety and control of CAR-T cell therapy. < Back Development in Synthetic Biology for Safe and Controlled CAR-T Cell Therapy Explore the revolutionary developments in Synthetic Biology for enhancing the safety and control of CAR-T cell therapy. There are promising results of adoptive T cell therapy, particularly chimeric antigen receptor T (CAR-T) cell therapy, in treating various malignancies; however, safety concerns such as cytokine release syndrome (CRS), immune effector cell–associated neurotoxicity syndrome (ICANS), and on-target off-tumor (OTOT) toxicity have emerged, prompting the application of synthetic biology to address these challenges. A recent review published by Science takes a step back and assess the current state of the field. The activation intensity of CAR-T cells is pivotal for effectiveness, leading to modifications incorporating costimulatory molecules. Yet, these changes often yield pronounced adverse effects. Current clinical approaches using interleukin-6 (IL-6) and IL-1 receptor antagonists may impact normal immune function. Synthetic biology, characterized by its systematic, modular, and standardised engineering, becomes a solution: by manipulating molecular components, it enables modular control of CAR-T cell behaviour, ensuring safety across temporal and spatial dimensions. Looking to the future, the rapid advancement of synthetic biology has produced sensors and gene circuits, showcasing promising outcomes in clinical trials for CAR-T cells. However, challenges like immunogenicity, expression leakage, and technical limitations persist. Future efforts must concentrate on minimizing immunogenicity, addressing gene circuit leakage, and enhancing gene delivery efficiency. Anticipate a future where CAR-T cells undergo sophisticated engineering, with synthetic biology providing diverse components, logic gates, and genetic circuits. The focus on universal CAR-T cells necessitates modifications to enhance safety. Thorough investigations into adverse effects are crucial for the development of safer, controllable, intelligent, and universal CAR-T cell therapies in future clinical treatments. Author BioFocus Newsroom Previous Next

In a major development, the FDA has approved Roche’s new drug, Itovebi, which offers a promising option for patients with advanced HER2-positive breast cancer. < Back Roche's New Breast Cancer Drug Itovebi Receives FDA Approval In a major development, the FDA has approved Roche’s new drug, Itovebi, which offers a promising option for patients with advanced HER2-positive breast cancer. Breast cancer treatments have evolved significantly in recent years, offering patients new options that target specific cancer types. Among these are therapies for HER2-positive breast cancer, an aggressive form characterized by the overexpression of the HER2 protein, leading to faster growth and spread. While advances in the field have improved outcomes, treatment for metastatic and advanced cases remains challenging. In a major development, the FDA has approved Roche ’s new drug, Itovebi, which offers a promising option for patients with advanced HER2-positive breast cancer. This approval allows Itovebi to be used in combination with Ibrance and Ibrance and Faslodex, produced by Pfizer and AstraZeneca , respectively. Itovebi joins several other innovative breast cancer treatments developed by Roche that target HER2-positive forms of the disease. Such therapies include: Herceptin (trastuzumab) – a groundbreaking monoclonal antibody that revolutionized HER2-positive breast cancer treatment by targeting the HER2 receptor. Perjeta (pertuzumab) – another HER2-directed monoclonal antibody, often used in combination with Herceptin. Kadcyla (T-DM1) – an antibody-drug conjugate that combines trastuzumab with chemotherapy to deliver targeted treatment. Itovebi, a HER2-directed antibody-drug conjugate, represents an innovative approach, delivering potent chemotherapy directly to cancer cells while limiting damage to healthy tissues. Roche's clinical trials have shown significant improvement in delaying disease progression when using the drug combination compared to existing treatments. This approval solidifies Roche's leadership in breast cancer treatment, while also positioning the company against competitors like Novartis and AstraZeneca, whose drugs, such as Kisqali and Enhertu, also target advanced breast cancer. By adding Itovebi to its portfolio, Roche aims to provide more personalized and effective treatment options for patients with this challenging diagnosis. Author BioFocus Newsroom Previous Next

< Back LIVX 2026 8th – 10th December, 2026 Dubai, UAE Hosting the most powerful global ecosystem for longevity, biotech, and investment. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

Innovative GLP-1 and amylin receptor agonist shows up to 22% weight reduction in early-stage study. < Back Novo Nordisk Unveils Promising Weight Loss Results from Amycretin Clinical Trial Innovative GLP-1 and amylin receptor agonist shows up to 22% weight reduction in early-stage study. Novo Nordisk has announced promising results from its phase 1b/2a clinical trial of amycretin, a novel once-weekly subcutaneous treatment for individuals with overweight or obesity. Amycretin is a unimolecular GLP-1 and amylin receptor agonist designed to aid weight loss. The trial assessed the safety, tolerability, pharmacokinetics, and efficacy of amycretin in 125 participants. The primary endpoint focused on treatment-emergent adverse events, which were consistent with those observed in incretin-based therapies. The most common side effects were gastrointestinal, predominantly mild to moderate in severity. Participants began with an average body weight of 92.7 kg. Those treated with amycretin experienced significant weight reductions: 1.25 mg dose (20 weeks): 9.7% weight loss 5 mg dose (28 weeks): 16.2% weight loss 20 mg dose (36 weeks): 22.0% weight loss In contrast, placebo recipients saw weight gains of 1.9%, 2.3%, and 2.0% over the same periods. Martin Lange, Novo Nordisk's executive vice president for Development, expressed optimism: "We are very encouraged by the subcutaneous phase 1b/2a results for amycretin in people living with overweight or obesity. The results seen in the trial support the weight-lowering potential of this novel unimolecular GLP-1 and amylin receptor agonist, amycretin, that we have previously seen with the oral formulation." Building on these findings, Novo Nordisk plans to advance amycretin's clinical development for adults with overweight or obesity. Amycretin represents a new class of treatment, combining GLP-1 and amylin receptor agonism, and is being developed for both oral and subcutaneous administration. Novo Nordisk, founded in 1923 and headquartered in Denmark, is a global healthcare leader aiming to combat serious chronic diseases. The company employs approximately 72,000 people across 80 countries and markets its products in around 170 countries. Author BioFocus Newsroom Previous Next

IGM Biosciences is discontinuing its lead autoimmune programs, imvotamab and IGM-2644, following disappointing clinical results, and implementing a 73% workforce reduction while reevaluating its strategic direction. < Back IGM Biosciences Halts Lead Autoimmune Programs, Cuts Workforce by 73% IGM Biosciences is discontinuing its lead autoimmune programs, imvotamab and IGM-2644, following disappointing clinical results, and implementing a 73% workforce reduction while reevaluating its strategic direction. IGM Biosciences , a clinical-stage biotechnology company, has announced a major shift in its strategic direction, discontinuing its lead autoimmune programs and implementing significant workforce reductions. The company cited disappointing interim results from clinical studies as the primary reason behind its decision. Key Programs Discontinued The company’s lead program, imvotamab, a CD20 x CD3 bispecific IgM antibody, was being developed to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Phase 1b trials revealed inconsistent and insufficient B cell depletion, a critical mechanism for the treatment of these autoimmune conditions. The company also discontinued its IGM-2644 program, a targeted effort to develop therapies for autoimmune and inflammatory diseases. Workforce and Financial Impact In response to these developments, IGM Biosciences announced a 73% workforce reduction, affecting approximately 144 employees. This restructuring is intended to conserve resources as the company re-evaluates its strategy. As of December 31, 2024, IGM reported $183.8 million in cash and investments, which will support the transition. Strategic Reevaluation Underway Dr. Mary Beth Harler, CEO of IGM Biosciences, expressed gratitude to the patients, investigators, and employees who contributed to the discontinued programs. She acknowledged the difficult but necessary decision to halt these projects and emphasized the company’s commitment to identifying new pathways to address unmet medical needs. IGM is now focused on assessing internal opportunities and exploring potential strategic alternatives to maximize shareholder value. Industry Implications The decision reflects the challenges of translating innovative therapeutic approaches into consistent clinical success. Analysts suggest that the company’s focus on IgM antibody technology, though promising, has struggled to deliver the required efficacy in autoimmune indications. Looking Forward While the discontinuation of these programs marks a setback, IGM’s proprietary IgM platform remains a potential asset for addressing other medical conditions. The company is expected to provide further updates as it refines its strategic priorities. This announcement follows a broader industry trend of biotech firms reassessing pipelines and conserving cash amid uncertain economic conditions and rising development costs. Author BioFocus Newsroom Previous Next

< Back CAR-T Therapy Drives Multi-Disease Remission Single treatment induces sustained remission across three autoimmune conditions, signalling expansion beyond oncology. A single administration of CD19-targeted CAR-T therapy has induced sustained, treatment-free remission across three severe autoimmune diseases, marking a significant inflection point in the clinical trajectory of engineered cell therapies beyond oncology. The findings, published in Med , describe a patient with refractory autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome who achieved rapid and durable remission following CAR-T infusion. Fourteen months post-treatment, the patient remains symptom-free and off all medication, despite previously failing nine lines of therapy. A Convergence of Three Refractory Diseases The clinical significance of the case lies not only in the severity of the individual conditions, but in their simultaneous presentation. The patient’s disease profile represents a convergence of B cell-mediated autoimmune pathologies, each associated with substantial morbidity and limited treatment durability. Prior to CAR-T intervention, the patient required continuous transfusion support and intensive pharmacological management, with no sustained response. The ability of a single therapeutic intervention to resolve all three conditions highlights a key mechanistic insight: these diseases, while clinically distinct, share a common immunological driver. Mechanism: Targeted Immune System Reset CAR-T therapy operates by engineering autologous T cells to recognise and eliminate CD19-expressing B cells, which are central to autoantibody production. In this case, depletion of pathogenic B cell populations resulted in: Rapid disappearance of circulating autoantibodies Restoration of normal haematological parameters Elimination of transfusion dependence within weeks Crucially, subsequent B cell reconstitution appeared to favour naïve, non-pathogenic populations, suggesting a functional “reset” of the immune system. This concept of immune reprogramming represents a fundamental departure from conventional immunosuppressive strategies, which typically require chronic administration and do not address underlying immune dysfunction. From Oncology to Autoimmune Disease CAR-T therapies have established clinical utility in haematological malignancies. Their application in autoimmune disease, however, represents a rapidly emerging frontier. Early clinical signals across multiple indications, including lupus and systemic sclerosis, have demonstrated the potential for deep and durable remission following a single treatment. What differentiates this case is the simultaneous resolution of multiple autoimmune conditions, extending the therapeutic hypothesis beyond single-disease targeting toward systemic immune recalibration. Clinical Significance and Limitations Despite the strength of the response, the study remains a single-patient case report and should be interpreted as hypothesis-generating rather than definitive evidence. Key limitations include: Lack of controlled clinical data Limited follow-up duration Uncertainty around long-term relapse risk Nevertheless, the findings align with a growing body of evidence suggesting that CD19-directed CAR-T therapy can induce deep remission in B cell–driven autoimmune diseases. Implications for Biopharma and Bioprocessing From an industry perspective, the implications extend well beyond clinical efficacy. Expansion of Addressable Markets The successful application of CAR-T in autoimmune disease significantly expands the potential patient population, moving beyond niche oncology indications into large, chronic disease segments. Manufacturing Pressure Unlike oncology use cases, broader autoimmune adoption will require: Increased manufacturing capacity Reduced cost of goods Streamlined, scalable production models Shift Toward One-Time Therapies If validated in larger trials, CAR-T could redefine treatment paradigms by replacing chronic immunosuppression with single-administration, potentially curative interventions. What Comes Next Multiple clinical trials are now underway to evaluate CAR-T therapies across a range of autoimmune indications, including lupus, multiple sclerosis, and vasculitis. However, key questions remain: Durability of remission beyond current follow-up periods Long-term safety and immune competence Optimal patient selection and treatment timing Author BioFocus Newsroom Previous Next

< Back 12th – 14th November, 2024 Boston, MA PMC Annual Personalized Medicine Conference The Annual Personalized Medicine Conference is designed to provide attendees with an opportunity to develop collaborative solutions to shared challenges in personalized medicine. Participants will exchange views with leading business executives, clinicians, journalists, and patient advocates in an intimate conference setting. Previous Register now Next

< Back 6th – 9th May, 2024 San Jose, CA SynBioBeta 2024 Where Global Leaders Shape the Future of Synthetic Biology. SynBioBeta 2024: The Global Synthetic Biology Conference brings the world’s leading innovators, investors, and industry pioneers to Silicon Valley from May 6–9, 2024. With 180+ expert-led sessions, 20+ curated networking experiences, and 200+ sponsors and exhibitors, this four-day event convenes over 2,500 attendees to explore the breakthroughs transforming science, industry, and society. Organized across four core themes and 18 in-depth tracks, SynBioBeta 2024 is the premier platform for advancing collaboration, accelerating innovation, and shaping the future of synthetic biology. Previous Register now Next

< Back 30th June – 3rd July, 2024 Rotterdam, Netherlands ECB2024 The Dutch Biotechnology Association (NBV) is pleased to host the World’s two longest running biotechnology Congresses, ECB2024 and IBS2024, at their annual meeting, NBC-24, in the Netherlands. Previous Register now Next

Astellas Pharma partners with AveXis to develop and commercialize AVXS-101, a promising gene therapy for Spinal Muscular Atrophy (SMA), aiming to expand treatment options for this rare and life-threatening genetic disorder. < Back Astellas and Avexis Collaborate on Gene Therapy for Spinal Muscular Atrophy Astellas Pharma partners with AveXis to develop and commercialize AVXS-101, a promising gene therapy for Spinal Muscular Atrophy (SMA), aiming to expand treatment options for this rare and life-threatening genetic disorder. Astellas Pharma Inc. (TSE: 4503) has announced a strategic partnership with AveXis, Inc., a Novartis company, to advance the development and commercialization of a gene therapy for Spinal Muscular Atrophy (SMA). The collaboration, aimed at expanding treatment options for this rare and debilitating neuromuscular disease, underscores Astellas’ commitment to addressing unmet medical needs in the field of genetic disorders. Under the terms of the agreement, Astellas will obtain exclusive rights to collaborate with AveXis on the continued development of AVXS-101 , a gene therapy for SMA. The partnership will focus on both the clinical development and the potential commercialization of this promising therapy in key global markets. Breakthrough Gene Therapy for SMA SMA is a rare genetic disorder caused by mutations in the SMN1 gene, leading to the degeneration of motor neurons, severe muscle weakness, and loss of motor function. It is one of the leading genetic causes of infant mortality, with an early onset of symptoms often resulting in significant health complications and, in many cases, premature death. AVXS-101 is an investigational one-time gene therapy designed to address the underlying cause of SMA by delivering a functional copy of the SMN1 gene to motor neurons, potentially halting disease progression or improving motor function. The therapy has already shown promising results in clinical trials, demonstrating significant improvements in motor function for patients with SMA, particularly for those with the most severe forms of the disease. If successfully commercialized, AVXS-101 could provide a transformative treatment option for SMA patients, offering hope for those affected by the condition and their families. Astellas' Commitment to Gene Therapy The collaboration with AveXis marks a significant milestone in Astellas’ growing portfolio of gene therapies. "Astellas is excited to partner with AveXis on this innovative gene therapy for SMA," said Yoshihiko Hatanaka, President and CEO of Astellas. "This collaboration reflects our ongoing commitment to advancing transformative therapies that address the root causes of diseases and bring meaningful improvements to patients’ lives." Astellas brings substantial expertise in developing and commercializing cutting-edge treatments, particularly in the field of rare diseases. The company’s experience in gene therapies, combined with AveXis’ leadership in SMA treatment development, positions the partnership to accelerate the availability of new, potentially life-changing options for SMA patients. Terms of the Partnership While the full financial details of the collaboration were not disclosed, the agreement includes both upfront payments and performance-based milestones, along with royalty payments based on future sales. Astellas will work closely with AveXis to progress AVXS-101 through further clinical development, regulatory approvals, and potential market entry. The collaboration is expected to facilitate the global expansion of gene therapies for SMA, with a focus on bringing the treatment to patients in regions such as the U.S., Europe, and Japan, where Astellas has a strong commercial presence. About Spinal Muscular Atrophy (SMA) SMA is a genetic disorder that affects approximately 1 in 6,000 to 10,000 live births worldwide. It leads to progressive muscle weakness and atrophy, primarily affecting infants and young children, with varying degrees of severity. Without early intervention, SMA can lead to respiratory failure and loss of motor function. However, with early diagnosis and treatment, patients can experience significant improvements in motor skills, mobility, and quality of life. About Astellas Pharma Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving the health of people around the world. With a focus on research and development in areas such as oncology, immunology, neuroscience, and rare diseases, Astellas is committed to bringing innovative therapies to patients. The company works to meet the unmet medical needs of patients, aiming to improve their quality of life and achieve better health outcomes. About AveXis (now Novartis Gene Therapies) AveXis, a Novartis company, is a leader in gene therapy with a focus on developing transformative treatments for patients with serious neurological genetic disorders. The company is particularly known for its work in SMA, where its groundbreaking gene therapy has shown to provide significant improvements in clinical outcomes. AveXis remains at the forefront of innovation in gene therapies for rare diseases. Author BioFocus Newsroom Previous Next